Published in Cancer Metastasis Rev on December 01, 2003
An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med (2009) 2.10
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol (2006) 2.07
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.99
Global impact of oncogenic Src on a phosphotyrosine proteome. J Proteome Res (2008) 1.94
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene (2010) 1.88
Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol Cancer Ther (2010) 1.67
Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. Br J Cancer (2006) 1.67
Src kinase phosphorylates Caspase-8 on Tyr380: a novel mechanism of apoptosis suppression. EMBO J (2006) 1.64
Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment. Clin Cancer Res (2010) 1.64
CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol Cell Biol (2007) 1.64
MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer Res (2011) 1.57
Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem (2010) 1.56
LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res (2010) 1.55
Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res (2008) 1.52
p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients. Proc Natl Acad Sci U S A (2010) 1.50
Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res (2009) 1.44
Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One (2008) 1.43
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. Br J Cancer (2009) 1.41
Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer (2009) 1.38
The involvement of the tyrosine kinase c-Src in the regulation of reactive oxygen species generation mediated by NADPH oxidase-1. Mol Biol Cell (2008) 1.37
Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer (2011) 1.34
Protein kinase Calpha activates c-Src and induces podosome formation via AFAP-110. Mol Cell Biol (2004) 1.33
Regulation of SRC family kinases in human cancers. J Signal Transduct (2011) 1.32
Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev (2012) 1.31
Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer Prev Res (Phila) (2011) 1.30
MicroRNA-218 is deleted and downregulated in lung squamous cell carcinoma. PLoS One (2010) 1.30
AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts. J Clin Invest (2007) 1.30
Novel p47(phox)-related organizers regulate localized NADPH oxidase 1 (Nox1) activity. Sci Signal (2009) 1.29
Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol (2010) 1.27
Involvement of Src family kinases in N-cadherin phosphorylation and beta-catenin dissociation during transendothelial migration of melanoma cells. Mol Biol Cell (2005) 1.24
Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration. Mol Carcinog (2010) 1.24
SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther (2008) 1.23
The dual kinase complex FAK-Src as a promising therapeutic target in cancer. Onco Targets Ther (2010) 1.22
IQGAP1-dependent signaling pathway regulates endothelial cell proliferation and angiogenesis. PLoS One (2008) 1.22
Targeting of erbB3 receptor to overcome resistance in cancer treatment. Mol Cancer (2014) 1.22
CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis. Proc Natl Acad Sci U S A (2011) 1.20
Emerging Roles for SSeCKS/Gravin/AKAP12 in the Control of Cell Proliferation, Cancer Malignancy, and Barriergenesis. Genes Cancer (2010) 1.20
Two N-myristoyltransferase isozymes play unique roles in protein myristoylation, proliferation, and apoptosis. Mol Cancer Res (2005) 1.20
c-Src-mediated phosphorylation of NoxA1 and Tks4 induces the reactive oxygen species (ROS)-dependent formation of functional invadopodia in human colon cancer cells. Mol Biol Cell (2010) 1.20
Understanding metastatic SCCHN cells from unique genotypes to phenotypes with the aid of an animal model and DNA microarray analysis. Clin Exp Metastasis (2006) 1.19
Current status of SRC inhibitors in solid tumor malignancies. Oncologist (2011) 1.18
Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res (2008) 1.16
Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene (2010) 1.16
Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma. Blood (2009) 1.15
Cdc42-interacting protein 4 promotes breast cancer cell invasion and formation of invadopodia through activation of N-WASp. Cancer Res (2010) 1.15
Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res (2012) 1.14
Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer. Cancer Res (2010) 1.14
Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells. Proc Natl Acad Sci U S A (2008) 1.13
Invading one step at a time: the role of invadopodia in tumor metastasis. Oncogene (2013) 1.13
Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Semin Oncol (2008) 1.12
Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis. Mol Carcinog (2010) 1.12
Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clin Breast Cancer (2011) 1.11
Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function. J Cancer Sci Ther (2009) 1.11
Transforming potential of Src family kinases is limited by the cholesterol-enriched membrane microdomain. Mol Cell Biol (2009) 1.10
RSK in tumorigenesis: connections to steroid signaling. Steroids (2010) 1.08
The adaptor protein Tom1L1 is a negative regulator of Src mitogenic signaling induced by growth factors. Mol Cell Biol (2006) 1.07
Increases in c-Yes expression level and activity promote motility but not proliferation of human colorectal carcinoma cells. Neoplasia (2007) 1.07
Src tyrosine kinase phosphorylation of nuclear receptor HNF4α correlates with isoform-specific loss of HNF4α in human colon cancer. Proc Natl Acad Sci U S A (2012) 1.07
Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition. Oncotarget (2014) 1.07
Identification of PTPN23 as a novel regulator of cell invasion in mammary epithelial cells from a loss-of-function screen of the 'PTP-ome'. Genes Dev (2011) 1.06
Src family kinases and paclitaxel sensitivity. Cancer Biol Ther (2011) 1.05
Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. PLoS One (2010) 1.05
Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Can Urol Assoc J (2011) 1.04
Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors. J Oncol (2009) 1.03
Odin (ANKS1A) is a Src family kinase target in colorectal cancer cells. Cell Commun Signal (2008) 1.03
Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Mol Cancer Ther (2008) 1.02
Tyrosine phosphorylation of cortactin by the FAK-Src complex at focal adhesions regulates cell motility. BMC Cell Biol (2011) 1.02
Oncogenic Src requires a wild-type counterpart to regulate invadopodia maturation. J Cell Sci (2010) 1.02
The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy. Clin Colorectal Cancer (2010) 1.01
Emerging evidence for the importance of phosphorylation in the regulation of NADPH oxidases. Antioxid Redox Signal (2009) 1.01
Src/FAK-mediated regulation of E-cadherin as a mechanism for controlling collective cell movement: insights from in vivo imaging. Cell Adh Migr (2011) 1.00
Modeling tumor invasion and metastasis in Drosophila. Dis Model Mech (2011) 1.00
EGFR-dependent pancreatic carcinoma cell metastasis through Rap1 activation. Oncogene (2011) 1.00
Paxillin-Y118 phosphorylation contributes to the control of Src-induced anchorage-independent growth by FAK and adhesion. BMC Cancer (2009) 0.99
Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor. Cancer Cell (2014) 0.99
Locking the active conformation of c-Src kinase through the phosphorylation of the activation loop. J Mol Biol (2013) 0.98
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. Invest New Drugs (2011) 0.98
A Fra-1-dependent, matrix metalloproteinase driven EGFR activation promotes human lung epithelial cell motility and invasion. J Cell Physiol (2008) 0.98
Src controls tumorigenesis via JNK-dependent regulation of the Hippo pathway in Drosophila. EMBO Rep (2012) 0.98
miR-203 suppresses the proliferation and migration and promotes the apoptosis of lung cancer cells by targeting SRC. PLoS One (2014) 0.98
Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells. Int J Cancer (2011) 0.97
Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines. Mol Cancer (2013) 0.96
Engineered kinase activation reveals unique morphodynamic phenotypes and associated trafficking for Src family isoforms. Proc Natl Acad Sci U S A (2014) 0.96
The prostaglandin E2 receptor, EP2, stimulates keratinocyte proliferation in mouse skin by G protein-dependent and {beta}-arrestin1-dependent signaling pathways. J Biol Chem (2010) 0.96
Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer. Clin Cancer Res (2010) 0.96
BCAR3 regulates Src/p130 Cas association, Src kinase activity, and breast cancer adhesion signaling. J Biol Chem (2009) 0.96
Simultaneous expression of caveolin-1 and E-cadherin in ovarian carcinoma cells stabilizes adherens junctions through inhibition of src-related kinases. Am J Pathol (2005) 0.95
Migfilin interacts with Src and contributes to cell-matrix adhesion-mediated survival signaling. J Biol Chem (2009) 0.95
Elevated MED28 expression predicts poor outcome in women with breast cancer. BMC Cancer (2010) 0.94
Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clin Exp Metastasis (2007) 0.93
p130Cas substrate domain signaling promotes migration, invasion, and survival of estrogen receptor-negative breast cancer cells. Breast Cancer (Dove Med Press) (2009) 0.93
PIKE GTPase are phosphoinositide-3-kinase enhancers, suppressing programmed cell death. J Cell Mol Med (2007) 0.93
Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer. Oncotarget (2015) 0.93
Ligand-independent activation of MET through IGF-1/IGF-1R signaling. Int J Cancer (2013) 0.92
IBD candidate genes and intestinal barrier regulation. Inflamm Bowel Dis (2014) 0.92
Combined inhibition of PLC{gamma}-1 and c-Src abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion. Clin Cancer Res (2008) 0.92
Increases in c-Src expression level and activity do not promote the growth of human colorectal carcinoma cells in vitro and in vivo. Neoplasia (2006) 0.92
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res (2009) 4.19
Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol (2007) 4.12
Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res (2009) 3.57
Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc (2009) 3.36
Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res (2008) 2.59
HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene (2005) 2.53
ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One (2011) 2.49
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol (2006) 2.07
Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer (2002) 2.03
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
Regulation of Cdc25C by ERK-MAP kinases during the G2/M transition. Cell (2007) 1.97
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res (2012) 1.92
Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res (2002) 1.88
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst (2006) 1.87
Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res (2005) 1.83
Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model. Clin Cancer Res (2003) 1.80
Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol (2003) 1.75
Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res (2006) 1.74
Src activation regulates anoikis in human colon tumor cell lines. Oncogene (2002) 1.70
The role of the guanine nucleotide exchange factor Tiam1 in cellular migration, invasion, adhesion and tumor progression. Breast Cancer Res Treat (2004) 1.69
Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun (2013) 1.62
Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest (2002) 1.57
Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol Cell Biol (2005) 1.55
CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res (2005) 1.54
Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem (2007) 1.54
Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res (2009) 1.54
Src continues aging: current and future clinical directions. Clin Cancer Res (2007) 1.50
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer (2011) 1.49
Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res (2003) 1.41
Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther (2006) 1.39
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res (2006) 1.38
Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer (2011) 1.34
Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Res (2005) 1.34
SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem (2007) 1.32
Involvement of the conserved adaptor protein Alix in actin cytoskeleton assembly. J Biol Chem (2006) 1.30
AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts. J Clin Invest (2007) 1.30
Tiam1 regulates cell adhesion, migration and apoptosis in colon tumor cells. Clin Exp Metastasis (2006) 1.26
The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs (2011) 1.24
BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res (2011) 1.23
Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy. Ann Surg Oncol (2011) 1.23
GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example. PLoS One (2009) 1.20
Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov (2013) 1.18
Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Res (2003) 1.17
AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells. J Cell Physiol (2007) 1.17
Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade. Cancer Res (2007) 1.14
c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK. Pancreas (2005) 1.14
AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol Cancer Ther (2005) 1.13
Pre-clinical mouse models of human prostate cancer and their utility in drug discovery. Curr Protoc Pharmacol (2010) 1.12
Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res (2008) 1.10
Src, chemoresistance and epithelial to mesenchymal transition: are they related? Anticancer Drugs (2007) 1.10
The guanine nucleotide exchange factor Tiam1 increases colon carcinoma growth at metastatic sites in an orthotopic nude mouse model. Oncogene (2005) 1.08
Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res (2011) 1.08
Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin. Clin Exp Metastasis (2003) 1.07
Neuropilin-1 suppresses tumorigenic properties in a human pancreatic adenocarcinoma cell line lacking neuropilin-1 coreceptors. Cancer Res (2005) 1.06
Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor. Ann Surg (2005) 1.06
Src activation of Stat3 is an independent requirement from NF-kappaB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells. Angiogenesis (2006) 1.03
Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors. Expert Opin Ther Targets (2007) 1.03
Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Mol Cancer Ther (2008) 1.02
Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis. Mol Cancer Res (2013) 1.01
Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells. Mol Ther (2005) 1.01
Decoding the intrinsic mechanism that prohibits ALIX interaction with ESCRT and viral proteins. Biochem J (2010) 0.98
A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis. Am J Pathol (2003) 0.97
SRC inhibitors as potential therapeutic agents for human cancers. Mini Rev Med Chem (2006) 0.96
Targeting SRC in mucinous ovarian carcinoma. Clin Cancer Res (2011) 0.93
Ligand-independent activation of MET through IGF-1/IGF-1R signaling. Int J Cancer (2013) 0.92
Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells. J Exp Ther Oncol (2007) 0.91
Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells. Cancer Res (2003) 0.91
Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. Int J Oncol (2007) 0.88
Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways. PLoS One (2012) 0.88
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Invest New Drugs (2012) 0.87
Src signaling pathways in prostate cancer. Cancer Metastasis Rev (2014) 0.86
A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Res (2012) 0.86
Extracellular Alix regulates integrin-mediated cell adhesions and extracellular matrix assembly. EMBO J (2008) 0.86
Plasticity in urokinase-type plasminogen activator receptor (uPAR) display in colon cancer yields metastable subpopulations oscillating in cell surface uPAR density--implications in tumor progression. Cancer Res (2006) 0.85
Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness. Clin Cancer Res (2004) 0.85
Targeting SRC and tubulin in mucinous ovarian carcinoma. Clin Cancer Res (2013) 0.83
Direct roles of the signaling kinase RSK2 in Cdc25C activation during Xenopus oocyte maturation. Proc Natl Acad Sci U S A (2010) 0.83
Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice. Int J Oncol (2006) 0.81
Src inhibitors in suppression of papillary thyroid carcinoma growth. Head Neck (2013) 0.80
AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor. Neuro Oncol (2010) 0.80
Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer. Prostate (2013) 0.78
Loss of tyrosine phosphatase-dependent inhibition promotes activation of tyrosine kinase c-Src in detached pancreatic cells. Mol Carcinog (2010) 0.78
Proteomics profiling of exosomes from primary mouse osteoblasts under proliferation versus mineralization conditions and characterization of their uptake into prostate cancer cells. J Proteome Res (2017) 0.75